Overview

A Randomized Phase II Study of Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

Status:
Not yet recruiting

Trial end date:
2028-02-28

Target enrollment:

Participant gender:

Summary

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.

Phase:

Phase 2

Details

Lead Sponsor:

Korea University Guro Hospital

Collaborators:

Boryung Pharmaceutical Co., Ltd
Chong Kun Dang Pharmaceutical Corp.
Yonsei University